The Aga Khan University (AKU) is a pioneering institution of higher education with a mission to improve the quality of life in the developing world and beyond, through world-class teaching, research and healthcare delivery. AKU educates students for local and global leadership from campuses and teaching hospitals in six countries, primarily in Asia and East Africa. It generates new knowledge to solve challenges that affect billions of people, especially the most vulnerable. The University is a private, not-for-profit institution and part of the Aga Khan Development Network.
The Centre for Regenerative Medicine (CRM) and Stem Cell Research is one of the most ambitious and mission-critical initiatives at AKU. Established in 2016, in collaboration with the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco (UCSF), the Centre is part of the Medical College in Pakistan. Integration with the research, clinical, and policy network of the Medical College enables access to, and engagement with, a broad intellectual network and interdisciplinary teams that include clinicians, basic scientists, students, health care leaders and decision makers. Engagement with Aga Khan University Hospital and its Clinical Trials Unit promotes clinical translation and priority-setting to enhance impact for patient benefit in the regions served by AKU.
The Centre has pioneered research in regenerative medicine and stem cell biology in Pakistan. Its mission is to translate fundamental research on regionally relevant diseases into novel therapies. With existing infrastructure at the Centre and related labs, AKU is well-positioned to lead in regenerative and genomic medicine regionally, transforming healthcare by incorporating technologies like next-generation sequencing, gene editing, and cell-based interventions.
The Centre comprises core research space for up to 28 bench researchers containing state-of the-art equipment, including a Fluorescence-activated Cell Sorter (FACS), confocal microscope, meta-system for chromosomal studies, a tissue regeneration laboratory with a bio-printer, three tissue culture facilities for induced Pluripotent Stem Cells (iPSC), primary patient sampling and quarantine, and an established cancer cell line laboratory.
To fully realize the promise of the Centre and a bench-to-bedside approach, AKU is investing further in a state-of-the-art Translational Research Facility (TRF) with integrated animal research, genomics, gene editing, induced pluripotent stem cell iPSC and GMP-grade laboratories to bridge the gap between laboratory research and clinical applications, such as gene and cellular therapies.